- Home
- PINS vs GMAB Comparison
PINS vs GMAB Comparison
Compare PINS & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PINS | GMAB |
|---|---|---|
| Founded | 2008 | 1999 |
| Country | United States | Denmark |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 19.1B |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | PINS | GMAB |
|---|---|---|
| Price | $18.21 | $26.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 28 | 7 |
| Target Price | $27.73 | ★ $40.93 |
| AVG Volume (30 Days) | ★ 22.2M | 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.61 | N/A |
| Revenue | ★ $4,221,767,000.00 | N/A |
| Revenue This Year | $14.64 | $17.80 |
| Revenue Next Year | $12.19 | $14.86 |
| P/E Ratio | $31.73 | ★ $1.90 |
| Revenue Growth | ★ 15.79 | N/A |
| 52 Week Low | $13.84 | $17.24 |
| 52 Week High | $39.93 | $35.43 |
Technical Indicators
Market Signals| Indicator | PINS | GMAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.31 | 31.78 |
| Support Level | $13.84 | $20.83 |
| Resistance Level | $27.86 | $33.75 |
| Average True Range (ATR) | 0.78 | 0.64 |
| MACD | 0.39 | -0.09 |
| Stochastic Oscillator | 49.36 | 1.98 |
Price Performance
Historical ComparisonAbout PINS Pinterest Inc.
Pinterest is a social media platform with a focus on product and idea discovery. Pinterest users, or pinners, can leverage the platform as they go about gathering ideas on topics such as home improvement, fashion, cooking, and travel. The company has more than 500 million monthly active users, two thirds of whom are female. Pinterest generates revenue by selling digital ads on its platform. While the platform's user base spans the globe, the vast majority of its revenue stems from ads shown to North American users.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.